183 related articles for article (PubMed ID: 20972709)
1. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Hubalek M; Brunner C; Matthä K; Marth C
Wien Med Wochenschr; 2010 Nov; 160(19-20):506-12. PubMed ID: 20972709
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Valabrega G; Montemurro F; Aglietta M
Ann Oncol; 2007 Jun; 18(6):977-84. PubMed ID: 17229773
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
Calabrich A; Fernandes Gdos S; Katz A
Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
[TBL] [Abstract][Full Text] [Related]
4. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC
J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276
[TBL] [Abstract][Full Text] [Related]
5. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
6. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
8. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
9. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS; Browne BC; Conlon NT; O'Brien NA; Slamon DJ; Henry M; Meleady P; Clynes M; Dowling P; Crown J; O'Donovan N
Mol Cancer; 2014 Jun; 13():157. PubMed ID: 24958351
[TBL] [Abstract][Full Text] [Related]
10. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
11. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Deng X; Fogh L; Lademann U; Jensen V; Stenvang J; Yang H; Brünner N; Schrohl AS
Tumour Biol; 2013 Apr; 34(2):1161-70. PubMed ID: 23334956
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
13. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
14. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
16. HER-2 signaling and inhibition in breast cancer.
Browne BC; O'Brien N; Duffy MJ; Crown J; O'Donovan N
Curr Cancer Drug Targets; 2009 May; 9(3):419-38. PubMed ID: 19442060
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Mukohara T
Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
[TBL] [Abstract][Full Text] [Related]
19. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
